D. Boral Capital Initiates Coverage on Plus Therapeutics (NASDAQ:PSTV)

D. Boral Capital began coverage on shares of Plus Therapeutics (NASDAQ:PSTV) in a research note released on Monday, MarketBeat.com reports. The firm issued a buy rating and a $9.00 target price on the stock.

A number of other research firms have also recently weighed in on PSTV. Ascendiant Capital Markets decreased their price target on Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating for the company in a report on Monday, December 9th. HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of Plus Therapeutics in a research note on Tuesday, November 26th.

Plus Therapeutics Stock Down 13.1 %

NASDAQ PSTV opened at $0.59 on Monday. The stock has a market cap of $3.48 million, a PE ratio of -0.23 and a beta of 0.73. Plus Therapeutics has a fifty-two week low of $0.24 and a fifty-two week high of $2.67. The business has a 50 day moving average price of $1.11 and a two-hundred day moving average price of $1.25.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.